Purpose/Objective (s) Nanomedicines are proving to be a viable option in improving
radiotherapeutic benefits by amplifying the effects of radiotherapy. A recently developed,
gadolinium (Gd) based theranostic agent has shown promise in the treatment of previously
difficult to treat tumors. Here we examine, for the first time, uptake of this agent in patients
with pancreatic cancer undergoing MR-guided adaptive radiotherapy. Materials/Methods
Data have been acquired from four patients with pancreatic cancer enrolled in a stereotactic …